They shift with the indication, the dose a clinician selects, individual biology, and how consistently the protocol is followed
We commonly use BPC-157 as part of our treatment for the following conditions: Chronic gastrointestinal (GI) issues, including colitis, Crohns disease, irritable bowel disease (IBD), gastritis, ulcers, and esophagitis
Follow-up shots are even faster
However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program
How quickly will I see results with peptide therapy
Thinking about peptides more generally Of course, peptides can have all kinds of activities